I agree that this site is using cookies. You can find further informations here.
X
Boér, Katalin
59  results:
Search for persons X
?
1

Opposite trends in incidence of breast cancer in young and ..:

Kiss, Zoltán ; Kocsis, Judit ; Nikolényi, Alíz...
Frontiers in Oncology.  13 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
2

Corrigendum: Systemic treatment of breast cancer. 1st Centr..:

Rubovszky, Gábor ; Kocsis, Judit ; Boér, Katalin...
Pathology and Oncology Research.  29 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
3

Systemic Treatment of Breast Cancer. 1st Central-Eastern Eu..:

Rubovszky, Gábor ; Kocsis, Judit ; Boér, Katalin...
Pathology and Oncology Research.  28 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
4

Pathologic Complete Response Rates After Neoadjuvant Pertuz..:

Boér, Katalin ; Kahán, Zsuzsanna ; Landherr, László...
Pathology and Oncology Research.  27 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
5

Demographic Characteristics and Treatment Patterns Among Pa..:

Boér, Katalin ; Rubovszky, Gábor ; Rokszin, György...
OncoTargets and Therapy.  14 (2021)  - p. 3971-3981 , 2021
Link: https://doi.org/10.2147/..
 
?
6

Overall survival results from the randomized phase 2 study ..:

Finn, Richard S. ; Boer, Katalin ; Bondarenko, Igor...
Breast Cancer Research and Treatment.  183 (2020)  2 - p. 419-428 , 2020
Link: https://doi.org/10.1007/..
 
?
7

Fulvestrant in advanced breast cancer: evidence to date and..:

Boér, Katalin
Therapeutic Advances in Medical Oncology.  9 (2017)  7 - p. 465-479 , 2017
Link: https://doi.org/10.1177/..
 
?
8

Impact of palbociclib combinations on treatment of advanced..:

Boér, Katalin
OncoTargets and Therapy.  9 (2016)  - p. 6119-6125 , 2016
Link: https://doi.org/10.2147/..
 
?
9

Efficacy and safety of palbociclib in combination with letr..:

Finn, Richard S. ; Crown, John P. ; Ettl, Johannes...
Breast Cancer Research.  18 (2016)  1 - p. , 2016
Link: https://doi.org/10.1186/..
 
?
10

Vandetanib with docetaxel as second-line treatment for adva..:

Boér, Katalin ; Láng, István ; Llombart-Cussac, Antonio...
Investigational New Drugs.  30 (2010)  2 - p. 681-687 , 2010
Link: https://doi.org/10.1007/..
 
?
11

A Phase II, open-label, randomised study to assess the effi..:

Bennouna, Jaafar ; Lang, Istvan ; Valladares-Ayerbes, Manuel...
Investigational New Drugs.  29 (2010)  5 - p. 1021-1028 , 2010
Link: https://doi.org/10.1007/..
 
?
12

Decreased expression of histamine H1 and H4 receptors sugge..:

Boer, Katalin ; Helinger, Eva ; Helinger, Andrea...
European Journal of Cell Biology.  87 (2008)  4 - p. 227-236 , 2008
Link: https://doi.org/10.1016/..
 
?
13

FROM DISCRETE‐TIME MODELS TO CONTINUOUS‐TIME, ASYNCHRONOUS ..:

Boer, Katalin ; Kaymak, Uzay ; Spiering, Jaap
Computational Intelligence.  23 (2007)  2 - p. 142-161 , 2007
Link: https://doi.org/10.1111/..
 
?
14

Impact of Systemic Histamine Deficiency on the Crosstalk Be..:

Hegyesi, Hargita ; Colombo, Lucas ; Pállinger, Éva...
Journal of Pharmacological Sciences.  105 (2007)  1 - p. 66-73 , 2007
Link: https://doi.org/10.1254/..
 
?
15

Corrigendum: Systemic treatment of breast cancer. 1st Centr..:

Rubovszky, Gábor ; Kocsis, Judit ; Boér, Katalin...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927865/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
1-15